In the past several decades, oncology drug development has had some major successes, from the approval of game-changing therapeutics such as rituximab and trastuzumab in the late-90s to the first tumor-agnostic approval for pembrolizumab in 2017.1...
![CTA_KRAS-CertiScreen-824x424-1-720x424 CTA_KRAS-CertiScreen-824x424-1-720x424](https://whitepapers.certisoncology.com/hs-fs/hubfs/CTA_KRAS-CertiScreen-824x424-1-720x424.jpg?width=720&name=CTA_KRAS-CertiScreen-824x424-1-720x424.jpg)
VALIDATE YOUR KRAS-TARGETING STRATEGY
Combining Predictive AI + Advanced Cancer Models to Help Direct Oncology Drug Development and Clinic Research Studies.
LEARN MORE![CTA_KRAS-CertiScreen-824x424-1-720x424 CTA_KRAS-CertiScreen-824x424-1-720x424](https://whitepapers.certisoncology.com/hs-fs/hubfs/CTA_KRAS-CertiScreen-824x424-1-720x424.jpg?width=720&name=CTA_KRAS-CertiScreen-824x424-1-720x424.jpg)
VALIDATE YOUR KRAS-TARGETING STRATEGY
Combining Predictive AI + Advanced Cancer Models to Help Direct Oncology Drug Development and Clinic Research Studies.
LEARN MORE